). The levels of total PKR were similar in all of the MDS samples analyzed when compared with BMMC from healthy donors (Figures 1a and 2a) . In contrast, while BMMC from healthy donors contained very low levels of p-PKR, an increase in the amount of p-PKR was detected in low-risk MDS patients (Figure 1b and Table 1 ). Interestingly, high-risk MDS cells showed not only an increased amount, but also a different subcellular localization, of p-PKR ( Figure 2b and Table 1 ). In fact, in these patients, about 50% of BMMC displayed a nuclear localization of p-PKR, whereas in low risk MDS patients and in healthy donors the staining was exclusively detected in the cytoplasm ( Figure 1 and Table 1 ). Our findings suggest that PKR could be somehow involved in the increased apoptosis seen in low risk MDS patients. Indeed, BMMC from low-risk MDS patients show increased levels of p-eIF2a when compared with healthy donors (data not shown). As to nuclear localization of p-PKR in BMMC from high-risk MDS patients, who are characterized by a lower apoptotic rate, it has been hypothesized that the nuclear translocation may be a mechanism to sequester active kinases, thus preventing upregulation of cytosolic signaling pathways. This is the case for phosphoinositide-dependent protein kinase-1, whose nuclear localization has been suggested to inhibit Akt-mediating signalling. 8 Therefore, it might be that active (phosphorylated) PKR is sequestered in the nucleus of BMMC from high risk MDS patients, who are characterized by a lower apoptotic rate. However, we could not rule out that nuclear localization of p-PKR in high-risk MDS patients is somehow linked to disease progression to AML. Further investigations are therefore needed to fully understand the functional role of PKR in both low-risk and high-risk MDS patients, nevertheless our findings suggest that also this protein kinase could be involved in the pathogenesis of MDS. Mutations in the kinase domain of BCR-ABL that impair drug binding are the best characterized mechanism of imatinib resistance in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia.
1 Some patients without kinase domain mutationbased resistance exhibit increased BCR-ABL expression. 2 However, in a sizable proportion of patients, neither of these mechanisms is demonstrable. 3 Causes of imatinib resistance implicated in such patients include insufficient intracellular drug levels due to increased efflux or reduced influx or sequestration of imatinib through increased plasma protein binding. 2 Further, some kinase domain mutation-negative patients appear to have truly BCR-ABL-independent imatinib resistance, for example, through the activation of SRC family kinases or adaptive granulocyte-macrophage colony-stimulating factor secretion. 4, 5 A myeloproliferative disease with features of CML can be induced by a variety of genetic lesions, including activating mutations of RAS, PTPN11, JAK2 and receptor tyrosine kinases such as FLT3. We therefore hypothesized that patients with acquired imatinib resistance but no evidence of BCR-ABL mutations or gene amplification may have activating mutations in such imatinib-insensitive pathways or that they may have acquired resistance mutations in the imatinib targets KIT and platelet-derived growth factor receptor a/b.
We identified a total of 17 imatinib-resistant CML patients (nine males and eight females) with a median age of 57 years (range: 34-69 years) (Table 1 ) who had no evidence of a BCR-ABL mutation on standard diagnostic sequencing. At the time of the study, cytogenetic analysis revealed a median of 40% (range: 10-100%) Ph-positive metaphases, fluorescence in situ hybridization showed a median of 43% (range: 1.5-98.5%) BCR-ABL-positive interphases, and quantitative PCR showed a BCR-ABL/G6PD median ratio of 2.5% (range: 0.52-210%). Out of the 17 patients, 10 never achieved a complete cytogenetic response before this study and seven had lost this level of response at the time of sampling. Sequence analysis of BCR-ABL covering the Cap, SH3, SH2 and kinase domains of ABL (exons 1-9) confirmed the absence of mutations. Mutation screening of KRAS (exons 3-5), NRAS (exons 2-5), PTPN11 (exons 3, 4, 8 and 13), KIT (entire coding region), FLT3 (exons 14 and 20), JAK2 (exon 14), PDGFRa (exons 12, 14 and 18) and PDGFRb (exons 11 and 17) revealed several previously described polymorphisms, but no novel mutations were detected. One of 17 patients (5.8%) harbored a missense mutation (C-T) in exon 3 of KRAS leading to replacement of threonine 58 with isoleucine (T58I). Approximately 30% of amplicons were mutant, as confirmed by bidirectional sequencing of three independently amplified PCR products.
The patient found to harbor the T58I KRAS mutation was a 62-year-old man with an 8-year history of chronic phase CML. He received initial therapy with interferon-a and cytarabine. In 2001, he was started on imatinib 400 mg daily and achieved a minor cytogenetic response that he subsequently lost, probably due to the appearance of a clone with a second copy of the Ph chromosome ( Table 2) . As a result, he was enrolled in a study combining imatinib 800 mg daily with arsenic trioxide. Abbreviations: ND, not determined; RT-PCR; reverse transcriptase PCR. Primary resistance was defined as the failure to achieve a major cytogenetic response (MCyR, o35% Ph+ metaphases) after at least 12 months of imatinib therapy. Suboptimal response was defined as 1-35% Ph-positive metaphases after 12 months of imatinib treatment. Relapse was defined by a loss of MCyR or CCyR at the time of the study. Fluorescence in situ hybridization (FISH) was performed on unseparated bone marrow interphase cells using the Vysis BCR/ABL dual fusion probe. BCR-ABL was measured in peripheral blood, normalized for expression of G6PD, and expressed in percent (BCR-ABL/G6PD), as described. 
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He achieved a transient major cytogenetic response. Upon relapse, he was switched to dasatinib. The T58I mutation was absent while the patient was responding to 800 mg of imatinib, but it became detectable before relapse and remained detectable (at approximately 30%) in 5 subsequent samples collected over a period of 18 months (Table 2) . During this time, the patient achieved a second major cytogenetic response on dasatinib. Immediately before relapse on dasatinib, the T58I allele became undetectable simultaneously with a rapid increase of the clone with the additional copy of Ph. None of the samples tested were positive for BCR-ABL kinase mutations at any time. T58I is an activating mutation of KRAS that has been previously reported in patients with Noonan syndrome who developed juvenile myelomonocytic leukemia.
7 KRAS mutations are associated with various other human cancers including colorectal cancers, though the specific T58I exchange has not been observed in these studies. 8 To assess the functional relevance of T58I in BCR-ABL-positive cells, we introduced KRAS T58I, KRAS G12D (a strongly activating mutation) and wild-type KRAS into 32D cells expressing BCR-ABL (32Dp210 BCRÀABL ) or parental 32D cells. Consistent with previous studies, 9 neither wild-type KRAS nor any of the mutants rendered parental 32D cells interleukin-3 independent (Figure 1a) . To test whether the KRAS T58I mutant may affect imatinib or dasatinib sensitivity, KRAS T58I-expressing 32Dp210 BCRÀABL cells were grown in the absence of interleukin-3 with graded concentrations of imatinib or dasatinib. Proliferation assays revealed a reduction in sensitivity to both imatinib and dasatinib in 32Dp210 BCRÀABL cells co-expressing wild-type or mutant KRAS. The effect was strongest with G12D, intermediate with T58I and weakest with wild-type KRAS. Notably, 15% of 32Dp210 BCRÀABL cells co-expressing KRAS Letters to the Editor T58I retained viability at 10 mM imatinib (Figure 1b) or 100 nM dasatinib ( Figure 1c) (Figure 1d ) or dasatinib (10 nM) (Figure 1e ) after 2 days in culture. Differences were less pronounced at higher concentrations of either drug. No effect was observed in 32D parental cells expressing wild-type or mutant KRAS (data not shown). Notably, our demonstration of KRAS T58I in a patient with imatinib resistance is analogous to findings by Lievre et al., 10 who identified other types of KRAS mutations in association with resistance to cetuximab, a drug targeting epidermal growth factor receptor in colorectal cancer. Thus, escape from the effects of tyrosine kinase inhibitor therapy by the activation of alternative pathways can occur in the setting of solid tumors as well as leukemia. Evidently, alternative therapies are required to treat this kind of resistance. In the case of RAS mutations, this could include Farnesyl transferase inhibitors or agents targeting the mitogen-activated protein kinase pathway.
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The transient appearance of a cell clone with an activating KRAS mutation could have two explanations. One possibility is that the KRAS mutant clone may have arisen independently of the CML clone and may be comparable to the Ph-negative but cytogenetically abnormal clones seen in some 5-10% of CML patients treated with imatinib, which are frequently transient. 12 Alternatively, as suggested by the temporal correlation with cytogenetic relapse, it is possible that the KRAS T58I mutant conferred partial resistance to imatinib, which promoted relapse and prevented the extinction of the clone on subsequent dasatinib therapy. Consistent with this, we found that co-expression of KRAS T58I and BCR-ABL in 32D cells reduced imatinib and dasatinib sensitivity, though not to the same degree as the strongly activating KRAS G12D mutation. Ultimately, a second clone, cytogenetically characterized by a second copy of the Ph chromosome, became dominant and suppressed the KRAS T58I clone below the detection threshold of direct sequencing. Distinguishing between these two possibilities would require single cell or colony assays, but unfortunately no suitable archived material is available.
Overall, our data show that activating RAS mutations may contribute to imatinib resistance in some CML patients who relapse with native BCR-ABL, although these mutations are apparently not a common mechanism of drug resistance in CML. In contrast, we found no evidence of mutations in PTPN11, JAK2, FLT3 or resistance mutations in the activation loops of KIT or PDGFRa/b in any of the 17 patients. Given that the cohort under study is small, however, it remains possible that such mutations would be detected in a larger group of patients. Additionally, the proportion of BCR-ABLpositive interphases was o50% in 7/17 samples. As direct sequencing was used for screening of KIT, KRAS, NRAS and JAK2, mutations present in the BCR-ABL-positive cells may have been missed, given that a mutant allele must be present at 420-25% to be detectable by this technique. This is less likely for mutations of PTPN11, FLT3 and PDGFRa/b, which were analyzed by D-HPLC with a sensitivity of approximately 10%. Irrespective of this, our data suggest that BCR-ABL mutation-negative resistance is not due to a frequent or universal mutation in one of the genes under study. Thus, in the majority of patients, other yet unknown mechanisms must account for resistance, and elucidating these mechanisms will be crucial for developing new therapeutic approaches. 11 
